Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease
- PMID: 2784281
- DOI: 10.1016/0002-9149(89)90249-x
Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease
Abstract
The acute hemodynamic and antiischemic effects of intravenous bepridil (3 mg/kg/5 minutes followed by 1 mg/kg/hour) were studied in 19 patients with coronary artery disease under basal conditions and during 2 identical pacing stress tests 30 minutes before (pace test I) and 15 minutes after (pace test II) onset of infusion. Bepridil immediately decreased coronary and systemic vascular resistance (26 and 17%, respectively). This resulted in a 19 and 21% reduction in left ventricular systolic and mean aortic pressures and a 15% increase in coronary flow and stroke index (p less than 0.05 vs control for each). These vasodilating effects were short lasting, persisting for 5 minutes after the bolus infusion, followed by significant reductions in heart rate (15%) and contractility (10%) and a temporary 46% increase in left ventricular filling pressure. During both pace tests heart rate, contractility, coronary flow and myocardial O2 consumption were comparable. In contrast, bepridil prevented the significant increase in systemic resistance and mean aortic pressure observed during pace test I (11 and 15%, respectively). Subsequently, myocardial O2 demand was significantly less during pacing after bepridil, due to an 11% reduction in left ventricular systolic pressure (p less than 0.05 vs control and pacing test II vs I). This resulted in marked antiischemic effects: normalization of lactate extraction and reduction in ST-segment depression (-14 +/- 7 vs 3 +/- 6% and 0.2 +/- 0.02 vs 0.13 +/- 0.02 mV, respectively, pace test I vs II, p less than 0.05), and in less or no angina in 18 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Acute antiischaemic properties of high dosages of intravenous diltiazem in humans in relation to its coronary and systemic haemodynamic effects.Eur Heart J. 1987 Sep;8(9):965-74. doi: 10.1093/oxfordjournals.eurheartj.a062373. Eur Heart J. 1987. PMID: 3665956
-
Dose related coronary and systemic haemodynamic effects of intravenous bepridil in patients with coronary artery disease.Eur Heart J. 1987 Feb;8(2):130-40. doi: 10.1093/oxfordjournals.eurheartj.a062240. Eur Heart J. 1987. PMID: 3494607
-
Effects on hemodynamics and left ventricular ejection fraction of intravenous bepridil for impaired left ventricular function secondary to coronary artery disease.Am J Cardiol. 1987 Jul 1;60(1):44-9. doi: 10.1016/0002-9149(87)90982-9. Am J Cardiol. 1987. PMID: 3496779
-
Hemodynamic effects of bepridil in patients with coronary artery disease.Am J Cardiol. 1992 Apr 9;69(11):17D-24D. doi: 10.1016/0002-9149(92)90954-w. Am J Cardiol. 1992. PMID: 1553887 Review.
-
Bepridil: a new long-acting calcium channel blocking agent.Drug Intell Clin Pharm. 1987 Jun;21(6):487-92. doi: 10.1177/106002808702100601. Drug Intell Clin Pharm. 1987. PMID: 3301244 Review.
Cited by
-
Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.Drugs. 1992 Nov;44(5):835-57. doi: 10.2165/00003495-199244050-00009. Drugs. 1992. PMID: 1280569 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources